Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Seismic Therapeutic Presents New Preclinical Results for S-1117 in Immune Thrombocytopenia at 66th ASH Meeting
Latest Hotspot
3 min read
Seismic Therapeutic Presents New Preclinical Results for S-1117 in Immune Thrombocytopenia at 66th ASH Meeting
12 December 2024
Seismic Therapeutic Unveils Fresh Preclinical Efficacy Results for S-1117 in Preventive and Treatment Animal Models of Immune Thrombocytopenia at the 66th ASH Meeting.
Read →
MTTI 225Ac-EBTATE Proves Extremely Potent in Combating Neuroendocrine Tumors
Latest Hotspot
3 min read
MTTI 225Ac-EBTATE Proves Extremely Potent in Combating Neuroendocrine Tumors
12 December 2024
Molecular Targeting Technologies, Inc. (MTTI) has released preclinical research findings for their proprietary 225Ac-EBTATE targeting SSTR2-positive neuroendocrine tumors (NET).
Read →
Merck's KEYLYNK-001 Study Achieves Main Goal in Advanced Ovarian Cancer
Latest Hotspot
3 min read
Merck's KEYLYNK-001 Study Achieves Main Goal in Advanced Ovarian Cancer
12 December 2024
Merck Reports Phase 3 KEYLYNK-001 Study Achieves Main Goal of Progression-Free Survival in Advanced Ovarian Cancer Patients.
Read →
Molecular Partners Shares MP0533 Clinical Updates and MP0621 Preclinical Insights at ASH 2024
Latest Hotspot
3 min read
Molecular Partners Shares MP0533 Clinical Updates and MP0621 Preclinical Insights at ASH 2024
12 December 2024
Molecular Partners Unveils Clinical Findings for MP0533 Study and Preclinical Insights on MP0621 at ASH 2024, Advancing Their Research Agenda.
Read →
C4 Therapeutics Presents Phase 1 Results on Cemsidomide as Promising IKZF1/3 Degrader
Latest Hotspot
3 min read
C4 Therapeutics Presents Phase 1 Results on Cemsidomide as Promising IKZF1/3 Degrader
12 December 2024
C4 Therapeutics Reveals Phase 1 Trial Results of Cemsidomide at the ASH Annual Meeting, Highlighting Its Potential as a Leading IKZF1/3 Degrader.
Read →
CS5001 Clinical Findings for Advanced Lymphoma Revealed at 66th ASH Conference
Latest Hotspot
3 min read
CS5001 Clinical Findings for Advanced Lymphoma Revealed at 66th ASH Conference
12 December 2024
Boosting Effectiveness and Security: CStone Unveils Recent Clinical Findings on CS5001 for Advanced Lymphoma at the 66th ASH Conference.
Read →
Innovent Reveals Phase 1 Trial Results for Anti-CLDN18.2 ADC in Pancreatic Cancer at ESMO Asia 2024
Latest Hotspot
3 min read
Innovent Reveals Phase 1 Trial Results for Anti-CLDN18.2 ADC in Pancreatic Cancer at ESMO Asia 2024
11 December 2024
Innovent unveiled new findings from its Phase 1 trial of the novel anti-CLDN18.2 ADC (IBI343) for advanced pancreatic cancer at the ESMO Asia Congress 2024.
Read →
Merck's Zilovertamab Vedotin and R-CHP Achieve 100% Complete Response in DLBCL Phase 2 Trial
Latest Hotspot
3 min read
Merck's Zilovertamab Vedotin and R-CHP Achieve 100% Complete Response in DLBCL Phase 2 Trial
11 December 2024
Merck's experimental drug Zilovertamab Vedotin combined with R-CHP achieved a complete response rate of 100% at a dosage of 1.75 mg/kg.
Read →
PureTech Presents LYT-200 Data for AML/MDS at 2024 ASH Meeting
Latest Hotspot
4 min read
PureTech Presents LYT-200 Data for AML/MDS at 2024 ASH Meeting
11 December 2024
PureTech showcases LYT-200 (anti-galectin-9 monoclonal antibody) data for relapsed/refractory AML/MDS at the 2024 ASH Annual Meeting.
Read →
Galapagos Unveils Promising Results from CD19 CAR T-Cell Trial in Non-Hodgkin Lymphoma
Latest Hotspot
3 min read
Galapagos Unveils Promising Results from CD19 CAR T-Cell Trial in Non-Hodgkin Lymphoma
11 December 2024
Galapagos Reveals Promising New Findings from Ongoing Phase 1/2 Trial of CD19 CAR T-Cell Treatment, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
Read →
Trial Shows Epcoritamab Combo Effective for Relapsed/Refractory Follicular Lymphoma
Latest Hotspot
3 min read
Trial Shows Epcoritamab Combo Effective for Relapsed/Refractory Follicular Lymphoma
11 December 2024
The clinical trial of Epcoritamab (DuoBody® CD3xCD20) combination therapy demonstrates significant response rates in patients with relapsed or refractory follicular lymphoma (FL).
Read →
WaveBreak's WTX-245 Shows Promise in Targeting TDP-43 Pathology for ALS and FTD
Latest Hotspot
4 min read
WaveBreak's WTX-245 Shows Promise in Targeting TDP-43 Pathology for ALS and FTD
11 December 2024
WaveBreak reveals initial preclinical results showing that the small molecule WTX-245 effectively inhibits the underlying causes of TDP-43 pathology.
Read →